Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Sep 13, 2025, 11:20 ET Radioligand Therapy (RLT) Market worth US$10.9 billion by 2035 with 13.2% CAGR | MarketsandMarkets™
cancer (mCRPC). Radioligand therapies such as Lutetium-177 vipivotide tetraxetan (Pluvicto) and emerging PSMA-targeted radiopharmaceuticals like [Lu-177]-PNT2002 and 177Lu-PSMA-I&T have demonstrated significant improvements in patient outcomes, including prolonged survival and better quality of life
More news about: MarketsandMarkets